Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

European Journal of Cancer: Supplement · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles